Cumberland Pharmaceuticals (CPIX) Income from Continuing Operations (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Income from Continuing Operations of 3140971.0 for Q1 2026, down 121.91% sequentially from 1415422.0 in Q4 2025, and down 351.64% YoY from 1248184.0 in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 3140971.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 351.64% year-over-year to 3140971.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7240646.0 (down 119.88% YoY) and the FY2025 annual result came in at 2851491.0, up 55.75% from the prior year.
- Income from Continuing Operations eased to 3140971.0 in Q1 2026 per CPIX's latest filing, from 1415422.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1248184.0 in Q1 2025 and troughed at 6301987.0 in Q4 2023.
- A 5-year average of 1436293.06 and a median of 1402433.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 1204.25% in 2024, then surged 165.61% in 2025.
- Over 5 years, Income from Continuing Operations stood at 2459714.0 in 2022, then plunged by 156.21% to 6301987.0 in 2023, then soared by 69.82% to 1901637.0 in 2024, then climbed by 25.57% to 1415422.0 in 2025, then plunged by 121.91% to 3140971.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 3140971.0, 1415422.0, and 1949046.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Cumberland Pharmaceuticals | 116.48 Mn | 112.62 Mn | - | -3.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.10 Mn |
| Mar 31, 2026 | -3.14 Mn |
| Dec 31, 2025 | -1.42 Mn |
| Sep 30, 2025 | -1.95 Mn |
| Jun 30, 2025 | -735,207.00 |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | -1.90 Mn |
| Sep 30, 2024 | -1.54 Mn |
| Jun 30, 2024 | -1.10 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -6.30 Mn |
| Sep 30, 2023 | -1.06 Mn |
| Jun 30, 2023 | 862,154.00 |
| Mar 31, 2023 | 172,286.00 |
| Dec 31, 2022 | -2.46 Mn |
| Sep 30, 2022 | -423,226.00 |
| Jun 30, 2022 | -1.36 Mn |
| Mar 31, 2022 | -1.40 Mn |
| Dec 31, 2021 | -4.39 Mn |
| Sep 30, 2021 | -1.58 Mn |